On August 17, 2021, the National Institute of Public Health released a rapid health technology assessment report on the evaluation of PD-L1 assays in urothelial carcinoma commissioned by the Ordering Forum (Bestillerforum for nye metoder). The current assessment summarizes systematic reviews examining the concordance between commercially available tests used for PD-L1 detection in the different forms of cancers and includes two systematic reviews:
- None of the included systematic reviews were limited to PD-L1 testing of urothelial carcinoma;
- Studies on PD-L1 testing of non-small cell lung cancer show a high degree of agreement between test results from 22C3, 28-8, and SP263. SP142 showed somewhat lower agreement compared to the other tests;
- There was a high degree of agreement between how PD-L1 expression was assessed by different pathologists and laboratories.
This assessment does not provide any conclusions on the effectiveness of various treatment strategies in the treatment of urothelial carcinoma in adults.
The full details in Norwegian can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.